Global Antithrombin III Deficiency Testing Market
Antithrombin deficiencies are mainly divided into two types: type I and type II. The type I antithrombin deficiency is characterized by an inadequate amount of normal antithrombin present in the bloodstream. In this condition, there is simply not enough antithrombin present to inactivate the coagulation factors. The type II antithrombin deficiency is characterized by adequate amount of antithrombin present in the bloodstream. However, it does not function properly and is unable to carry out its normal functions.
A sample of this report is available upon request @ www.persistencemarketresearch.com/samples/4272
Antithrombin III is a non-vitamin, K-dependent protease that naturally blocks abnormal blood clot formation in the bloodstream. Deficiency of antithrombin III causes various blood clot disorders in the human body. For instance, congenital antithrombin III deficiency is a common antithrombin deficiency, which usually occurs when individuals receive the abnormal antithrombin III gene from their parents. This abnormal gene causes abnormal blood clots in the human body which block blood flow and damage organs.
The major symptoms of blood clotting include fainting, coughing up blood, shortness of breath, pain when taking deep breaths, and swelling of legs. In addition, some physical symptoms of blood clots are abnormal lung sounds, fast breathing, swollen foot or leg, and fast heart rate.
The global antithrombin III deficiency testing market is categorized on the basis of various types of deficiencies, diagnostic procedures, and end users. Based on the type of deficiencies, the report covers type I antithrombin deficiency and type II antithrombin deficiency. Based on the type of technology, the report covers monoclonal antibodies, molecular diagnostics, differential light scattering, immunoassays, flow cytometry, chromatography, gel micro droplets, diagnostic imaging, and others. Based on end users, the report covers commercial or private labs, physician offices, hospitals, public health labs, and academic research institutes.
In terms of geography, North America dominates the global antithrombin III deficiency testing market. This is due to increased government funding on healthcare infrastructure in the region. In addition, technological advancement in antithrombin III diagnostic procedures has also propelled the market in North America. The U.S. represents the largest market for antithrombin deficiency testing in North America, followed by Canada. In Europe, Germany, France, and the U.K. hold the major shares of the antithrombin III deficiency testing market. The antithrombin III deficiency testing market in Asia is also expected to show high growth rates in the next five years. This is due to the various initiatives undertaken by governments to increase awareness about blood clotting disorders in the region. In addition, increased investments by many foreign diagnostic instrument companies have also propelled the growth of the antithrombin III deficiency testing market in the region. India, China, and Japan are expected to be the fastest-growing markets for antithrombin III deficiency testing in Asia.
Advanced applications of antithrombin deficiency diagnostic instruments and increasing prevalence of blood clot disorders are the key drivers for the global antithrombin III deficiency testing market. Also, increased government support in the form of funding and rapid technological advancements have fueled the growth of this market.
An increasing number of mergers and acquisitions involving diagnostic consumables manufacturing companies and rapid product launches are the key trends in the global antithrombin III deficiency testing market.
To view TOC of this report is available upon request @ www.persistencemarketresearch.com/toc/4272
The major companies operating in this market are Abbott Laboratories, Avocet Medical Inc., Axis-Shield plc, Beckman Coulter Inc., Becton, Dickinson and Company, Trinity Biotech PLC, Thermo Fisher Scientific, Inc., Siemens AG, Roche, Chrono-log Corporation, Sysmex Corporation, Hyphen Biomed and American Diagnostica GmbH.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Antithrombin III Deficiency Testing Market here
News-ID: 484096 • Views: 614
More Releases from Persistence Market Research Pvt. Ltd
Innovative Rehabilitation Technologies Drive Growth in Stroke Rehabilitation Mar …
Stroke Rehabilitation Market Size The global stroke rehabilitation market size was valued at US$ 266.4 million in 2021 and is expected to grow at a CAGR of 9% from 2022 to 2032. Revenue generated from the sales of stroke rehabilitation solutions will surge to US$ 679.6 Million by the end of 2032. The growth of the market is being driven by the increasing incidence of strokes, the growing demand for innovative rehabilitation
Launch of New Laser-Based Devices by Key Players Fueling Growth of Global Aesthe …
Market Study on Aesthetic Lasers The aesthetic lasers market reached US$2.8 billion in global revenue in 2021, and it will continue to expand quickly, with a value CAGR of 6.4%, to reach US$5.5 billion by the end of 2032. The growth of the market is being driven by the increasing demand for minimally invasive cosmetic procedures, rising disposable income, technological advancements, and growing medical tourism. Stay Ahead with Market Intelligence Get Free
Predictive Insights for Precision Medicine: The Global Biosimulation Market is S …
Biosimulation Market Research The Global Biosimulation Market Size was valued at USD 2.9 billion in 2022 and is expected to reach USD 10.0 billion by 2030, registering a CAGR of 16.9% during the forecast period. The growth of the biosimulation market is being driven by the increasing use of biosimulation in a variety of applications, such as drug discovery, clinical trials, and toxicity prediction. Market Overview The biosimulation market has experienced rapid growth
Wheelchair and Components Market: Growing Demand for Lightweight and Smart Wheel …
Wheelchair and Components Market The global wheelchair and components market is projected to reach USD 17.9 billion by 2033, at a CAGR of 3.7% from 2022-2033. The growth of the market is driven by the increasing prevalence of disabilities, the rising geriatric population, and technological advancements in wheelchair design and manufacturing. Click Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/12961 The global wheelchair and components market has witnessed significant growth in
More Releases for III
STEIGER DYNAMICS launches LEET III HTPC Chassis
REDWOOD CITY (December 27th, 2021) – STEIGER DYNAMICS just released the third iteration of its critically acclaimed LEET HTPC case. Except for a few subtle but elegant changes in design, LEET III Chassis shares the same one-piece, hand-brushed, full-aluminum shell that made its predecessors so iconic. Accompanied by the 7” front LED display that features our own LEET Monitor app, and full open-loop liquid cooling support, LEET III Chassis redefines
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipelin …
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems. Download the sample report @ https://www.pharmaproff.com/request-sample/1146 In later stages of this disorder, people
EXCEEMO Industrial SATA III SSD
Extremely impressive performance, the highest reliability and guaranteed fixed BOM - all in one service package for industrial customers EXCEEMO, the memory and storage specialist from Landsberg am Lech, presents the industrial 2.5“ SATA III Solid-State-Drives with ultra-fast read/write transfer speed of up to 555MB/515MB per second and proven long-term reliability. The noiseless, energy-efficient and particularly robust solid state drives are available both in standard grade (0°/+70°C-MLC/SLC) and in industrial
BioFocus extends collaboration with Usher III Initiative
BioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision. BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a
NewBlueFX Introduces “Video Essentials III” Effects Plugins
NewBlueFX Introduces “Video Essentials III” Effects Plugins The Video Editor’s Wish List of Tools & Techniques in One Package Video, Multimedia and Technology Editors LA JOLLA, CA (November 04, 2009)— NewBlue, Inc. today launched Video Essentials III, the third and latest offering in its best-selling Video Essentials series of video effects and transitions plugins. NewBlue Video Essentials III provides highly-practical video tools designed to solve everyday production issues. The collection includes Rolling Shutter,
ZOTAC Preps for 100th Warcraft III Cup
HONG KONG – Aug. 17, 2009 – ZOTAC International, an industry leader in motherboards and graphics cards manufacturing, today announces the 100th tournament in the ZOTAC Warcraft III: The Frozen Throne Cup is coming Aug. 22 with a special prize. To mark the 100th tournament of the ZOTAC Warcraft III: The Frozen Throne Cup, the winner will be rewarded with a high-end ZOTAC GeForce series graphics card in addition to